Cidara Therapeutics (CDTX) News Today → The 1,000X Crypto Playbook (From True Market Insiders) (Ad) Free cdtx Stock Alerts $12.00 -0.71 (-5.59%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 4:04 PM | markets.businessinsider.comBuy Rating Justified by Cidara Therapeutics’ Upcoming Clinical Trials and Expanding Oncology PipelineMay 16 at 11:03 AM | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 16 at 8:30 AM | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Cidara Therapeutics in a report on Thursday.May 16 at 12:04 AM | msn.comCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024May 15 at 7:04 PM | stockhouse.comROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXMay 15 at 7:04 PM | sfgate.comCidara Therapeutics: Q1 Earnings SnapshotMay 15 at 4:20 PM | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15 at 4:01 PM | globenewswire.comCidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 10, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Short Interest UpdateCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 83,700 shares, an increase of 920.7% from the April 15th total of 8,200 shares. Based on an average daily volume of 60,900 shares, the days-to-cover ratio is presently 1.4 days. Currently, 2.0% of the shares of the company are sold short.May 10, 2024 | prnewswire.comCDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXApril 26, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 26, 2024 | finance.yahoo.comCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 25, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Given Average Recommendation of "Buy" by BrokeragesShares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have received an average recommendation of "Buy" from the four brokerages that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a buy rating and one has given a stronApril 25, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst UpgradeCidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst UpgradeApril 25, 2024 | marketbeat.comWBB Securities Reaffirms "Strong-Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX)WBB Securities reissued a "strong-buy" rating and set a $40.00 price target on shares of Cidara Therapeutics in a report on Thursday.April 25, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) PT Raised to $25.00 at Needham & Company LLCNeedham & Company LLC increased their target price on Cidara Therapeutics from $3.00 to $25.00 and gave the company a "buy" rating in a report on Thursday.April 25, 2024 | businesswire.comCDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTXApril 24, 2024 | msn.comCidara Therapeutics shares surge 30% after reacquiring flu treatmentApril 24, 2024 | marketwatch.comCidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu AssetApril 24, 2024 | msn.comCidara stock rallies amid $240M private placement, drug updateApril 24, 2024 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Shares Up 7.1%Cidara Therapeutics (NASDAQ:CDTX) Shares Up 7.1%April 24, 2024 | globenewswire.comCidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 MillionApril 24, 2024 | globenewswire.comCidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC PipelineApril 24, 2024 | marketbeat.comTrading was temporarily halted for "CDTX" at 07:04 PM with a stated reason of "News pending."April 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Receipt of Nasdaq Delinquency NoticeApril 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 23, 2024 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for Cidara Therapeutics (NASDAQ:CDTX)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cidara Therapeutics in a research report on Tuesday.April 22, 2024 | investorplace.comCDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023April 22, 2024 | msn.comWhy Cidara Therapeutics (CDTX) Stock Is FallingApril 22, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 22, 2024 | globenewswire.comCidara Therapeutics Announces Receipt of Nasdaq Delinquency NoticeApril 22, 2024 | globenewswire.comCidara Therapeutics Announces Reverse Stock SplitApril 14, 2024 | seekingalpha.comCDTX Cidara Therapeutics, Inc.April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program DevelopmentsApril 8, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX)HC Wainwright reaffirmed a "buy" rating and issued a $6.00 price target on shares of Cidara Therapeutics in a report on Monday.April 7, 2024 | investing.comCidara Therapeutics reveals promising cancer therapy dataApril 5, 2024 | globenewswire.comCidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024March 30, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Drop in Short InterestCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 179,500 shares, a decline of 18.9% from the February 29th total of 221,400 shares. Based on an average daily volume of 713,100 shares, the short-interest ratio is presently 0.3 days.March 20, 2024 | marketbeat.comCidara Therapeutics (CDTX) Set to Announce Quarterly Earnings on ThursdayCidara Therapeutics (NASDAQ:CDTX) will be releasing earnings on Thursday, March 21, Yahoo Finance reports.March 17, 2024 | finance.yahoo.comCidara Therapeutics, Inc. (CDTX)March 13, 2024 | insidertrades.comInsider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) CFO Sells 18,931 Shares of StockMarch 12, 2024 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) CFO Sells $12,683.77 in StockCidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) CFO Preetam Shah sold 18,931 shares of Cidara Therapeutics stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $0.67, for a total transaction of $12,683.77. Following the sale, the chief financial officer now owns 227,210 shares in the company, valued at approximately $152,230.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 9, 2024 | edition.cnn.comCidara Therapeutics, Inc.March 6, 2024 | finance.yahoo.comCidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024February 15, 2024 | finance.yahoo.comSteven Cohen's Point72 Adds Cidara Therapeutics to Its PortfolioFebruary 12, 2024 | msn.comCidara receives $11M milestone payment from partner MundipharmaFebruary 12, 2024 | marketwatch.comCidara Therapeutics Gets $11.1M Milestone Payment for RezzayoFebruary 12, 2024 | markets.businessinsider.comCidara Receives Milestone Payment From Mundipharma On European Approval Of REZZAYOFebruary 12, 2024 | finance.yahoo.comCidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden replacement revealed? (Ad)A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13. See his shocking evidence in this new report CDTX Media Mentions By Week CDTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.660.55▲Average Medical News Sentiment CDTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼152▲CDTX Articles Average Week Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Entera Bio News Today Genenta Science News Today LENZ Therapeutics News Today Aligos Therapeutics News Today AVROBIO News Today Ikena Oncology News Today Turnstone Biologics News Today Elutia News Today Atara Biotherapeutics News Today Instil Bio News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersGold Set to EXPLODE!Gold Safe ExchangeCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
